Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series
- PMID: 25888085
- DOI: 10.1016/S0140-6736(15)60038-1
Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series
Abstract
Background: Orthotopic heart transplantation is the gold-standard long-term treatment for medically refractive end-stage heart failure. However, suitable cardiac donors are scarce. Although donation after circulatory death has been used for kidney, liver, and lung transplantation, it is not used for heart transplantation. We report a case series of heart transplantations from donors after circulatory death.
Methods: The recipients were patients at St Vincent's Hospital, Sydney, Australia. They received Maastricht category III controlled hearts donated after circulatory death from people younger than 40 years and with a maximum warm ischaemic time of 30 min. We retrieved four hearts through initial myocardial protection with supplemented cardioplegia and transferred to an Organ Care System (Transmedics) for preservation, resuscitation, and transportation to the recipient hospital.
Findings: Three recipients (two men, one woman; mean age 52 years) with low transpulmonary gradients (<8 mm Hg) and without previous cardiac surgery received the transplants. Donor heart warm ischaemic times were 28 min, 25 min, and 22 min, with ex-vivo Organ Care System perfusion times of 257 min, 260 min, and 245 min. Arteriovenous lactate values at the start of perfusion were 8·3-8·1 mmol/L for patient 1, 6·79-6·48 mmol/L for patient 2, and 7·6-7·4 mmol/L for patient 3. End of perfusion lactate values were 3·6-3·6 mmol/L, 2·8-2·3 mmol/L, and 2·69-2·54 mmol/L, respectively, showing favourable lactate uptake. Two patients needed temporary mechanical support. All three recipients had normal cardiac function within a week of transplantation and are making a good recovery at 176, 91, and 77 days after transplantation.
Interpretation: Strict limitations on donor eligibility, optimised myocardial protection, and use of a portable ex-vivo organ perfusion platform can enable successful, distantly procured orthotopic transplantation of hearts donated after circulatory death.
Funding: NHMRC, John T Reid Charitable Trust, EVOS Trust Fund, Harry Windsor Trust Fund.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
Cardiac donation after circulatory death: a time to reflect.Lancet. 2015 Jun 27;385(9987):2554-6. doi: 10.1016/S0140-6736(15)60683-3. Epub 2015 Apr 14. Lancet. 2015. PMID: 25888087 No abstract available.
Similar articles
-
Cardiac donation after circulatory death: a time to reflect.Lancet. 2015 Jun 27;385(9987):2554-6. doi: 10.1016/S0140-6736(15)60683-3. Epub 2015 Apr 14. Lancet. 2015. PMID: 25888087 No abstract available.
-
Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment.Ont Health Technol Assess Ser. 2020 Mar 6;20(3):1-90. eCollection 2020. Ont Health Technol Assess Ser. 2020. PMID: 32190164 Free PMC article.
-
Recovery of donor hearts after circulatory death with normothermic extracorporeal machine perfusion.Eur J Cardiothorac Surg. 2015 Jan;47(1):173-9; discussion 179. doi: 10.1093/ejcts/ezu117. Epub 2014 Apr 11. Eur J Cardiothorac Surg. 2015. PMID: 24727935
-
Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial.Lancet. 2015 Jun 27;385(9987):2577-84. doi: 10.1016/S0140-6736(15)60261-6. Epub 2015 Apr 14. Lancet. 2015. PMID: 25888086 Clinical Trial.
-
Donation after circulatory death heart transplantation.Curr Opin Organ Transplant. 2017 Jun;22(3):189-197. doi: 10.1097/MOT.0000000000000419. Curr Opin Organ Transplant. 2017. PMID: 28379853 Review.
Cited by
-
Artemisinin Attenuates Transplant Rejection by Inhibiting Multiple Lymphocytes and Prolongs Cardiac Allograft Survival.Front Immunol. 2021 Feb 24;12:634368. doi: 10.3389/fimmu.2021.634368. eCollection 2021. Front Immunol. 2021. PMID: 33717174 Free PMC article.
-
Pushing the boundaries of innovation: the potential of ex vivo organ perfusion from an interdisciplinary point of view.Front Cardiovasc Med. 2023 Oct 12;10:1272945. doi: 10.3389/fcvm.2023.1272945. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37900569 Free PMC article. Review.
-
Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs.Biomater Sci. 2024 Jul 23;12(15):3866-3881. doi: 10.1039/d3bm01908j. Biomater Sci. 2024. PMID: 38910521 Free PMC article.
-
The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart disease.Biophys Rev. 2017 Aug;9(4):431-441. doi: 10.1007/s12551-017-0305-3. Epub 2017 Aug 14. Biophys Rev. 2017. PMID: 28808947 Free PMC article. Review.
-
Donation After Circulatory Death: A New Frontier.Curr Cardiol Rep. 2022 Dec;24(12):1973-1981. doi: 10.1007/s11886-022-01798-y. Epub 2022 Oct 22. Curr Cardiol Rep. 2022. PMID: 36272050 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical